Literature DB >> 2501102

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier.

H L Wiener1, A Hashim, A Lajtha, H Sershen.   

Abstract

L-Deprenyl is an inhibitor of monoamine oxidase B and dopamine uptake. Chronic L-deprenyl (10 mg/kg i.p., twice weekly for 4 weeks) was shown to inhibit monoamine oxidase B activity by 89%, and also to induce an up-regulation of the [3H]mazindol binding site associated with the striatal dopamine uptake carrier. Scatchard analysis indicated a 56% increase in the maximal number of [3H]mazindol binding sites in chronic L-deprenyl animals, but no effect on the affinity of these binding sites. The ability of L-deprenyl to up-regulate the [3H]mazindol-associated dopamine uptake carrier appears to be a result of its role as a dopamine uptake inhibitor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501102     DOI: 10.1016/0014-2999(89)90418-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

2.  Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.

Authors:  I Lamensdorf; S Porat; R Simantov; J P Finberg
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  Unaltered [3H]GBR-12935 binding after chronic treatment with dopamine active drugs.

Authors:  P Allard; K Eriksson; S B Ross; J O Marcusson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  A Review of Sleep and Its Disorders in Patients with Parkinson's Disease in Relation to Various Brain Structures.

Authors:  Isobel T French; Kalai A Muthusamy
Journal:  Front Aging Neurosci       Date:  2016-05-23       Impact factor: 5.750

5.  Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Elena Shumay; Fred McCall-Perez; Millard Jayne; Gene-Jack Wang; David L Alexoff; Karen Apelskog-Torres; Barbara Hubbard; Pauline Carter; Payton King; Stanley Fahn; Michelle Gilmor; Frank Telang; Colleen Shea; Youwen Xu; Lisa Muench
Journal:  Neuropsychopharmacology       Date:  2014-09-24       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.